Omid Raiesi

Dr. Omid Raiesi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
ZBZeinab Borjian Boroujeni
Zeinab Borjian Boroujeni
SSSina Shamsaei
Sina Shamsaei
MYMohammad Yarahmadi
Mohammad Yarahmadi
MGMuhammad Ibrahim Getso
Muhammad Ibrahim Getso
AKAlireza Salimi Khorashad
Alireza Salimi Khorashad
OROmid Raiesi
Omid Raiesi

17 January 2020 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
OROmid Raiesi
Omid Raiesi
ATAli Taghipour
Ali Taghipour
ZNZahra Navi
Zahra Navi
SESoudabeh Etemadi
Soudabeh Etemadi
ZSZahra Sohrabi
Zahra Sohrabi
OROmid Raiesi
Omid Raiesi

18 June 2020 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
SSS. Shamsaei
S. Shamsaei
MGMuhammad Ibrahim Getso
Muhammad Ibrahim Getso
KAK. Ahmadikia
K. Ahmadikia
MYM. Yarahmadi
M. Yarahmadi
HFH. E. Farahani
H. E. Farahani
OROmid Raiesi
Omid Raiesi

1 October 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
SSSina Shamsaei
Sina Shamsaei
MFMehraban Falahati
Mehraban Falahati
SFShirin Farahyar
Shirin Farahyar
OROmid Raiesi
Omid Raiesi
LHLeila Haghighi
Leila Haghighi
MKMahyar Keymaram
Mahyar Keymaram

1 April 2021 in Comparative Immunology, Microbiology and Infectious Diseases
Verified
Journal Article
Closed access
OROmid Raiesi
Omid Raiesi
MMMohammad Taqi Masoumi
Mohammad Taqi Masoumi
AIAsmaa Ibrahim
Asmaa Ibrahim
SESoudabeh Etemadi
Soudabeh Etemadi
MGMuhammad Getso
Muhammad Getso
OROmid Raiesi
Omid Raiesi

1 May 2022 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
MMMoein Mohseni
Moein Mohseni
VRVahid Raissi
Vahid Raissi
YSYasamin Sharifan
Yasamin Sharifan
KBKimia Barikro
Kimia Barikro
SASasan Amiri
Sasan Amiri
OROmid Raiesi
Omid Raiesi
The novel coronavirus, SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread worldwide. More than 272 million cases of infection have been identified. COVID-19 has affected 223 countries and territories across the world. The principal target of the SARS-CoV-2 infection is the lower respiratory tract. Series of moderate to non-specific severe clinical signs and symptoms appear two to fourteen days after exposure to SARS-CoV-2 in patients with COVID-19 disease, including cough, breath deficiency, and at least two of these symptoms: headache, fever, chills, repeated rigor, myalgia, oropharyngitis, anosmia, and ageusia. No therapeutic agents have been validated to have substantial efficacy in the clinical care of COVID-19 patients in large-scale trials, despite worsening infected rates of COVID-19. Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortality. The mechanism by which famotidine could improve the outcomes of COVID-19 is currently unknown. A more recent postulated mechanism is that the effect of famotidine is mediated by histamine-2 receptor antagonism or inverse agonism, inferring that the SARS-CoV-2, resulting in COVID-19 infection, at least partially leads to the abnormal release of histamine and perhaps dysfunction of mast cells.